When sorting through a heap of antibody candidates from a library, antibody affinity and binning data are critical for sorting through potential candidates. Twist Biopharma, a division of Twist Bioscience, uses its proprietary DNA writing technology
to create large diverse oligo pools (upwards of 106) to develop a range of antibody phage display libraries. These libraries are either broadly applicable to any target or focused on a specific class of tough targets, e.g. GPCRs.
Screening Twist’s libraries often discovers a large panel of antibodies to each target, which can be further sorted based on affinity and epitope.
Throughput, speed, resolution, and sample consumption are typically key limiting- factors for detailed kinetic characterization early in antibody discovery campaigns. Here, we show that high throughput surface plasmon resonance (SPR) can be used
to rapidly generate high quality kinetic data from 384 antibodies in parallel with minimal sample consumption. Additionally, epitope binning assays can be performed on up to 384 antibodies per array, providing unprecedented throughput that
allows for early assessment of your library’s epitope coverage with exquisite epitope discrimination, facilitating the identification of clones targeting unique epitopes. The ability to characterize binding kinetics, affinity, and epitope
specificity on large antibody panels with minimal sample consumption at early stage research is highly advantageous in drug discovery because it helps to accelerate library-to-lead triage.
In this webinar, Twist Biopharma will show how the Carterra fits into their workflow to get an early read on affinity and epitope binning. Utilizing this data, they will show how they can winnow their lead candidates down to a smaller number of
top candidates to pursue further.
- Understand how the synthetic biology revolution has relieved a bottleneck in the antibody space
- The value of high throughput SPR technologies for antibody affinity, specificity, and binning
- Understand the value of high throughput antibody production coupled with complementary screening platforms
Aaron K. Sato, Ph.D.
Twist Biopharma, a division of Twist Bioscience
Aaron is CSO of the Biopharma Vertical at Twist Bioscience. Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw
all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He also held director level positions at both Oncomed and Dyax Corp.
Daniel H. Bedinger, Ph.D.
Application Science Team Lead
Dan is the lead application scientist at Carterra, where he has helped to develop and commercialize a high throughput SPR instrument for antibody screening. Prior to joining Carterra, he had a twelve-year career at XOMA contributing to then leading
a bioanalytical team that applied label-free biosensors to the discovery of therapeutic antibodies. Dan graduated from University of California Davis with a PhD in Molecular, Cellular, and Integrative Physiology studying the function of allosteric
insulin receptor modulating mAbs. He has been working in the field of monoclonal antibody drug discovery since the year 2000 and co-authored over 15 peer-reviewed papers, many of which emphasize the application of biosensors in drug discovery.